Synthetic dipeptide inspired by a toxin from the temple viper's venom (waglerin-1), sold as a topical 'Botox effect'. The published evidence is computational and laboratory-based; there are no independent human trials.
FDA (US): Not approved as a drug (sold as a cosmetic ingredient)
EMA (EU): Not authorized as a drug (cosmetic ingredient in the EU)
Dose
There is no established dose in humans.
Safety
In topical cosmetics it is usually well tolerated; it may cause local irritation or redness. There are no long-term safety data or data in pregnancy. Do a patch test on a small area before using it.
Effect by goal · level of evidence
Anti-aging activity in laboratory models
improvesLowin vitro (A)animals / laboratory
Computer simulations showed stable binding to MMP-13 and SIRT1, and in laboratory tests it scavenged free radicals in a dose-dependent manner, with no toxicity or mutagenicity at the doses tested. It does not include people.
It was designed to mimic waglerin, which blocks the muscle acetylcholine receptor and thus relaxes the muscle. In computer studies it also binds to collagen-degrading enzymes (MMPs) and to sirtuin 1, and in the test tube it has some antioxidant activity.
What the evidence says
In people
There are no published trials in people.
In animals or the laboratory
Anti-aging activity in laboratory models. Computer simulations showed stable binding to MMP-13 and SIRT1, and in laboratory tests it scavenged free radicals in a dose-dependent manner, with no toxicity or mutagenicity at the doses tested. It does not include people. PubMed 37349941